SRA's number for the day: 50
This article was originally published in SRA
Executive Summary
Almost 50 nanomedicines and nano-imaging agents are currently in Phase I-III studies in Europe, with others further behind in development. In addition, some 70 cancer trials involving nanomedicines are under way in the US.